Core Viewpoint - TG Therapeutics Inc. is recognized as one of the best revenue growth stocks to consider for investment, with analysts maintaining positive ratings despite some adjustments in price targets [1][3]. Group 1: Analyst Ratings and Price Targets - JPMorgan analyst Brian Cheng reduced the price target for TG Therapeutics from $49 to $46 while keeping an Overweight rating on the shares [1]. - H.C. Wainwright analyst Emily Bodnar assigned a Buy rating, highlighting the company's strong commercial momentum and expected clinical catalysts in 2026 [3]. - TD Cowen analyst Tara Bancroft reiterated a Buy rating and set a price target of $50 for TG Therapeutics [3]. Group 2: Clinical Developments - TG Therapeutics presented trial results for its Briumvi treatment for relapsing multiple sclerosis at a medical forum in San Diego on February 6 [3]. - The anticipated clinical catalysts include results for consolidated IV dosing and a self-administered subcutaneous formulation for Briumvi, which could enhance its market share against competitors [3].

Group 1 - Newmont Corporation (NYSE:NEM) is a mining company focused on gold production and exploration, as well as seeking other metals like copper, silver, zinc, and lead [2] - In 2025, Newmont's stock gained 168%, reflecting a significant surge in gold prices [2] - Jim Cramer expressed a preference for Agnico Eagle Mines over Newmont but acknowledged that investing in gold mining stocks is generally favorable given the strong performance of gold [2] Group 2 - There is a belief that certain AI stocks may offer greater upside potential and carry less downside risk compared to Newmont [3] - The article suggests that there are undervalued AI stocks that could benefit from current economic trends, indicating a shift in investment focus [3]

Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer commented on. Cramer highlighted the company’s post-earnings decline, as he remarked: What went wrong at Novo Nordisk? Yesterday, the Danish drug maker behind Ozempic reported, and the stock plunged nearly 15% before sinking another 6% today. While the quarter was fine, the guidance, let’s just say it was brutal. They’re talking about a 5% to 13% sales hit this year, thanks to pricing pressures amid fierce competition for the GLP-1 business. It s ...

Core Viewpoint - Enterprise Products Partners L.P. (NYSE:EPD) is recognized as one of the best pipeline and MLP stocks to buy in 2026, reflecting positive long-term prospects in the energy infrastructure sector [1]. Analyst Ratings - Mixed sentiment exists among analysts regarding Enterprise Products Partners L.P. On January 28, 2026, RBC Capital maintained a Buy rating with a price target of $35, while Morgan Stanley issued a Sell rating with a price target of $34 [2]. - Earlier, on January 16, 2026, Scotiabank maintained a Sector Perform rating and raised the price target from $34 to $35, citing increasing power demand and significant LNG exports as drivers for long-term earnings [3]. Analyst Consensus - According to CNN, 57% of 23 analysts have assigned a Buy rating to Enterprise Products Partners L.P., with a 1-year median price target reflecting a 4.98% increase [4]. Company Overview - Founded in 1968, Enterprise Products Partners L.P. is based in Texas and provides services for natural gas, NGLs, crude oil, and petrochemicals through a comprehensive network of pipelines, storage, and processing assets [4].

Group 1 - Kinder Morgan, Inc. (NYSE:KMI) is recognized as one of the 11 Best Pipeline and MLP Stocks to Buy in 2026 [1] - Freedom Capital upgraded Kinder Morgan's rating from Sell to Hold on January 28, 2026, with a price target of $32, citing limited upside potential but anticipating strong Q1 2026 due to rising seasonal gas demand [2] - Jefferies analyst Julien Dumoulin Smith reiterated a Hold rating on Kinder Morgan with a price target of $31 on January 26, 2026 [3] Group 2 - Kinder Morgan reported Q4 2025 earnings on January 21, 2026, showing a 10% year-over-year growth in adjusted EBITDA and a 22% growth in adjusted EPS, driven by natural gas expansions and the Outrigger acquisition [4] - The company operates an extensive network of approximately 82,000 miles of pipelines and 139 terminals, specializing in the transportation and storage of natural gas, crude oil, and CO2 [5]

Core Viewpoint - Plains All American Pipeline, L.P. (NASDAQ:PAA) is recognized as one of the best pipeline and MLP stocks to buy in 2026, despite mixed analyst ratings and price targets from various financial institutions [1]. Analyst Ratings and Price Targets - RBC Capital and Morgan Stanley have maintained their Hold ratings on PAA, with price targets of $20 and $21 respectively as of January 28, 2026 [2]. - BofA downgraded PAA's rating from Neutral to Underperform, setting a lower price target of $19 [2]. - Mizuho raised its price target for PAA from $22 to $23 while maintaining an Outperform rating, highlighting a positive outlook on the company's transition to a pure-crude portfolio [3]. Market Sentiment and Company Overview - The 1-year median target for PAA from 20 analysts is 7.09%, indicating a cautious but slightly optimistic sentiment [4]. - Founded in 1998, PAA is a midstream master limited partnership focused on the transportation, storage, and marketing of crude oil and NGLs, operating a significant infrastructure network across the U.S. and Canada [4].

Group 1 - Petco Health and Wellness Company Inc. (NASDAQ:WOOF) has completed its long-term debt refinancing, aiming to enhance financial flexibility and reduce leverage [1][2] - The refinancing involved $1.5 billion of its current term loan, including a $50 million voluntary prepayment due in December 2025 and the issuance of $600 million in senior secured notes at an annual interest rate of 8.25% [1] - Glenn Murphy has transitioned from Executive Chairman to Chairman of the Board of Directors, effective February 1, 2024, during a significant transformation period for the company [2] Group 2 - Petco operates over 1,500 stores across the U.S., Mexico, and Puerto Rico, offering a range of pet-oriented products and services, including veterinary care, grooming, training, tele-health, and pet health insurance [3]

Core Viewpoint - GoodRx Holdings Inc. (NASDAQ:GDRX) is facing challenges that have led to a downgrade by Jefferies, impacting its stock outlook and price target [1][2]. Group 1: Company Performance - Jefferies downgraded GoodRx from Buy to Hold and reduced the price target from $5.25 to $2.75 [1]. - The company has experienced a 14% year-over-year decline in monthly active consumers and a 9% drop in prescription revenues due to the Rite Aid bankruptcy and the closure of 800 pharmacy locations [1]. - Prescription revenues are expected to remain flat year-over-year, with challenges in the prescription discount segment, which constitutes about 69% of the company's expected revenue [2]. Group 2: Financial Outlook - Analysts project that overall revenue and EBITDA growth for GoodRx will remain muted, leading to stagnant valuation multiples in the short term [2].

Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $3 to invest in. On February 4, Opko Health Inc. (NASDAQ:OPK) announced it expanded its partnership with Entera Bio Ltd., a company developing oral peptide and protein replacement therapies, to advance the first oral long-acting PTH analog (LA-PTH) treatment for patients with hypoparathyroidism, in the form of a once-daily tablet. The two companies have also jointly decided to accelerate development on this medication and expect to file an Inves ...

Core Viewpoint - Gildan Activewear Inc. is considered one of the most undervalued Canadian stocks, with multiple analysts raising their price targets in anticipation of positive developments related to the Hanesbrands integration strategy and overall market positioning [1][2][3]. Group 1: Analyst Ratings and Price Targets - Scotiabank increased its price target for Gildan Activewear to $72 from $66 while maintaining an Outperform rating, reflecting confidence in the company's positioning within the apparel industry [1]. - TD Securities analyst raised the price target for Gildan Activewear to $77 from $74 with a Buy rating, emphasizing the importance of the Hanesbrands integration strategy for investor confidence [2]. - BMO Capital raised its price target for Gildan Activewear to $78 from $70 with an Outperform rating, highlighting the company's low-cost, vertically integrated manufacturing model as a driver for wholesale growth and market share capture [3]. Group 2: Company Overview - Gildan Activewear Inc. manufactures and sells a variety of apparel products, including activewear and hosiery under several brands such as Gildan, GoldToe, and All Pro [4].